Arbutus Reports Third Quarter 2019 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Arbutus Biopharma (ABUS) Misses Q3 EPS by $1.11
November 6, 2019 7:40 AM ESTArbutus Biopharma (NASDAQ: ABUS) reported Q3 EPS of ($1.50), $1.11 worse than the analyst estimate of ($0.39).
We remain committed to our mission of developing a portfolio of assets with differing mechanisms of action that we believe will form the basis for a functional cure of chronic... More
